EP3656768A1 - Beraprost-314d crystals and methods for preparation thereof - Google Patents

Beraprost-314d crystals and methods for preparation thereof Download PDF

Info

Publication number
EP3656768A1
EP3656768A1 EP19211631.7A EP19211631A EP3656768A1 EP 3656768 A1 EP3656768 A1 EP 3656768A1 EP 19211631 A EP19211631 A EP 19211631A EP 3656768 A1 EP3656768 A1 EP 3656768A1
Authority
EP
European Patent Office
Prior art keywords
beraprost
solvent
crystalline form
pattern
precipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19211631.7A
Other languages
German (de)
French (fr)
Inventor
Shih-Yi Wei
Jian-Bang Jheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chirogate International Inc
Original Assignee
Chirogate International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chirogate International Inc filed Critical Chirogate International Inc
Publication of EP3656768A1 publication Critical patent/EP3656768A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates in general to solid forms of prostacyclin derivatives and in particular, to solid crystalline forms of Beraprost-314d and preparation methods thereof.
  • Beraprost is a synthetic benzoprostacyclin analogue of natural prostacyclin consisting of four isomers (Beraprost-314d, Beraprost-314d's enantiomer, Beraprost-315d and Beraprost-315d's enantiomer), as shown in Scheme A.
  • optically pure Beraprost-314d (termed as Esuberaprost, APS-314d or BPS-314d) is the pharmacologically active isomer, and is currently under clinical trials as an added-on active pharmaceutical ingredient in the inhaled treprostinil (Tyvaso®) for the treatment of diseases, such as pulmonary arterial hypertension in North America and Europe.
  • the preparation of Beraprost-314d has been previously described, e.g., in Heterocycles, 2000, 53, 1085-1092 , US 8779170 , and WO 2017/174439 .
  • a stable solid form of Beraprost-314d crystal can be widely used in storage, shipment, and handling for commercial considerations. Additionally, a stable Beraprost-314d crystal having fixed physicochemical properties can provide constant operating parameters, e.g., solubility for regular pharmaceutical formulation and steady bioabsorbability for pharmacological treatment.
  • WO 2017/174439 discloses a crystalline form of Beraprost-314d (termed as Form I). However, it does not disclose the stability data of Beraprost-314d crystal Form I, so it is uncertain whether there exists a crystalline form transformation for Beraprost-314d crystal Form I or not.
  • the present invention provides a stable solid form of Beraprost-314d crystal Form II, and processes for the preparation thereof.
  • the present invention provides a method for preparing a crystalline Form II of Beraprost-314d, which comprises dissolving Beraprost-314d in a first solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, toluene, xylene, acetone, dichloromethane, 1,4-dioxane, tetrahydrofuran, methanol, ethanol, propanol, butanol, and mixtures thereof to form a homogenous solution; lowering the temperature and/or adding a second solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane
  • the present invention provides a crystalline Form II of Beraprost-314d having an X-ray powder diffraction (XRPD) pattern exhibiting its five strongest characteristic peaks at the following 2 ⁇ reflection angles: 6.1 ⁇ 0.2°, 6.6 ⁇ 0.2°, 7.2 ⁇ 0.2°, 12.1 ⁇ 0.2°, and 16.3 ⁇ 0.2°.
  • XRPD X-ray powder diffraction
  • the present invention provides a crystalline Form II of Beraprost-314d having a differential scanning calorimetry (DSC) thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 62.2 ⁇ 1°C and a peak maximum of approximately 67.5 ⁇ 1°C.
  • DSC differential scanning calorimetry
  • the present invention provides a solid form of Beraprost-314d crystal Form III, and processes for the preparation thereof.
  • the present invention provides a method for preparing a crystalline Form III of Beraprost-314d, which comprises dissolving Beraprost-314d in a third solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, ethyl acetate, isopropyl acetate, dichloromethane, and mixtures thereof to form a homogenous solution; lowering the temperature and/or adding a fourth solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogenous solution; and stirring until a precipitate is formed.
  • a third solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, e
  • the present invention provides a crystalline Form III of Beraprost-314d having an XRPD pattern exhibiting its five strongest characteristic peaks at the following 2 ⁇ reflection angles: 6.2 ⁇ 0.2°, 7.2 ⁇ 0.2°, 12.4 ⁇ 0.2°, 15.7 ⁇ 0.2°, and 19.3 ⁇ 0.2°.
  • the present invention provides a crystalline Form III of Beraprost-314d having a DSC thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 61.9 ⁇ 1°C and a peak maximum of approximately 66.2 ⁇ 1°C.
  • the present invention provides a solid form of Beraprost-314d crystal Form II, which can remain stable when stored at room temperature without crystalline transformation for commercial use.
  • the prepared Beraprost-314d crystal Form III will slowly convert to Form II while keeping at room temperature It is further proved that the solid form of Beraprost-314d crystal Form II is the most stable form of Beraprost-314d.
  • the method for preparing Beraprost-314d crystal Form II comprises the steps of:
  • the first solvent used to dissolve the crude Beraprost-314d is selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, toluene, xylene, acetone, dichloromethane, 1,4-dioxane, tetrahydrofuran, methanol, ethanol, propanol, butanol, and mixtures thereof, preferably ethyl acetate and isopropyl acetate.
  • the volume of the first solvent may be about 0.5 ml to about 100 ml, preferably about 1 ml to about 50 ml, and more preferably about 2 ml to about 25 ml, per 1 g of the crude Beraprost-314d.
  • the volume is preferably about 20 ml or more.
  • the crude Beraprost-314d can be dissolved in the first solvent at a temperature ranging from about 0°C to about 80°C, preferably from about 10°C to about 70°C, and more preferably from room temperature to about 60°C.
  • the temperature of the homogenous solution is lowered to a temperature ranging from about -30°C to about 60°C, preferably from about -20°C to about 50°C, and more preferably from about -10°C to about 40°C.
  • the volume of the second solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof may be about 0.5 ml to about 40 ml or about 30 ml or about 20 ml, preferably about 1 ml to about 10 ml, and more preferably about 2 ml to about 5 ml, per 1 ml of the first solvent.
  • the second solvent can be added at a temperature ranging from about -30°C to about 60°C, preferably from about -20°C to about 50°C, and more preferably from about -10°C to about 40°C.
  • the precipitation of the crystal may be performed at a temperature ranging from about -30°C to about 60°C, preferably from about -20°C to about 50°C, and more preferably from about -10°C to about 40°C.
  • the mixture is stirred in an ice water bath (about 0 ⁇ 5°C) for a time period, such as for about 18 hours or more, until the precipitate is formed.
  • the step of filtering out the precipitate comprises using the second solvent or a mixture of the first solvent and the second solvent to wash the precipitate.
  • the ratio of the first solvent and the second solvent may be about 1:1 to about 1:100, preferably about 1:2 to about 1:10.
  • the Beraprost-314d crystal Form II has an X-ray powder diffraction (XRPD) pattern exhibiting its five strongest characteristic peaks at the following 2 ⁇ reflection angles: 6.1 ⁇ 0.2°, 6.6 ⁇ 0.2°, 7.2 ⁇ 0.2°, 12.1 ⁇ 0.2°, and 16.3 ⁇ 0.2°.
  • the XRPD pattern further comprises characteristic peaks at the following 2 ⁇ reflection angles: 14.3 ⁇ 0.2°, 19.5 ⁇ 0.2°, 19.7 ⁇ 0.2°, 20.6 ⁇ 0.2°, 20.9 ⁇ 0.2°, 21.4 ⁇ 0.2°, 22.3 ⁇ 0.2°, 23.2 ⁇ 0.2°, 24.8 ⁇ 0.2°, and 26.6 ⁇ 0.2°.
  • the XRPD pattern of Beraprost-314d crystal Form II is consistent with Fig. 1 .
  • the particular data of Beraprost-314d crystal Form II is shown in Table 1.
  • Table 1 2 ⁇ angle (°) d value ( ⁇ ) relative intensity (%) 6.1 14.6 100.0 6.6 13.4 46.1 7.2 12.4 40.9 10.4 8.5 12.9 12.1 7.3 69.0 13.1 6.7 11.1 14.3 6.2 27.6 16.3 5.4 82.4 16.9 5.2 14.5 17.5 5.1 7.4 17.9 5.0 15.8 18.4 4.8 6.0 19.1 4.6 13.8 19.5 4.6 35.0 19.7 4.5 28.5 20.2 4.4 11.0 20.6 4.3 18.2 20.9 4.3 25.4 21.4 4.1 21.9 22.3 4.0 27.8 22.6 3.9 11.9 23.2 3.8 32.4 24.0 3.7 3.5 24.8 3.6 20.6 26.3 3.4 10.3 26.6 3.4 22.0 27.1 3.3 4.1 27.6 3.2 9.2 28.1 3.2 5.2 28.4 3.1
  • the present invention provides a Beraprost-314d crystal Form II having an XRPD pattern substantially as shown in Fig.1 .
  • the present invention provides a Beraprost-314d crystal Form II having a differential scanning calorimetry (DSC) thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 62.2 ⁇ 1°C and a peak maximum of approximately 67.5 ⁇ 1°C.
  • DSC differential scanning calorimetry
  • the present invention provides a Beraprost-314d crystal Form II having a DSC thermogram pattern substantially as shown in Fig. 2 .
  • the precipitated Beraprost-314d crystal Form II Due to the organic solvent system used in the method of the present invention, the precipitated Beraprost-314d crystal Form II possesses compact solid characteristics and thus is easy to be filtered out. Moreover, the residual solvents can be easily removed under high vacuum at room temperature.
  • Beraprost-314d crystal Form II is a stable crystalline form, which shows good stability, with no other crystalline forms or degraded products of impurities, even after six months of placement under normal storage temperatures (about -20°C).
  • the method for preparing Beraprost-314d crystal Form III comprises the steps of:
  • the third solvent used to dissolve the crude Beraprost-314d is selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, ethyl acetate, isopropyl acetate, dichloromethane, and mixtures thereof, preferably methyl tert-butyl ether and dichloromethane.
  • the volume of the third solvent may be about 0.5 ml to about 100 ml, preferably about 1 ml to about 50 ml, and more preferably about 2 ml to about 25 ml, per 1 g of the crude Beraprost-314d.
  • the volume is preferably about 20 ml or more.
  • the crude Beraprost-314d can be dissolved in the third solvent at a temperature ranging from about 0°C to about 80°C, preferably from about 10°C to about 70°C, and more preferably from room temperature to about 60°C.
  • the temperature of the homogenous solution is lowered to a temperature ranging from about 0°C to about 60°C, preferably from about 10°C to about 50°C, and more preferably from about 20°C to about 40°C.
  • the volume of the fourth solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof may be about 0.5 ml to about 40 ml or about 30 ml or about 20 ml, preferably about 1 ml to about 10 ml, and more preferably about 2 ml to about 5 ml, per 1 ml of the third solvent.
  • the fourth solvent can be added at a temperature ranging from about 0°C to about 60°C, preferably from about 10°C to about 50°C, and more preferably from about 20°C to about 40°C.
  • the mixture is stirred at room temperature (about 20 ⁇ 25°C) for a time period, such as for about 18 hours or more, until the precipitate is formed.
  • the precipitation of the crystal may be performed at a temperature ranging from about 0°C to about 60°C, preferably from about 10°C to about 50°C, and more preferably from about 20°C to about 40°C.
  • the step of filtering out the precipitate comprises using the fourth solvent or a mixture of the third solvent and the fourth solvent to wash the precipitate.
  • the ratio of the third solvent and the fourth solvent may be about 1:1 to about 1:100, preferably about 1:2 to about 1:10.
  • the Beraprost-314d crystal Form III has an XRPD pattern exhibiting its five strongest characteristic peaks at the following 2 ⁇ reflection angles: 6.2 ⁇ 0.2°, 7.2 ⁇ 0.2°, 12.4 ⁇ 0.2°, 15.7 ⁇ 0.2°, and 19.3 ⁇ 0.2°.
  • the XRPD pattern further comprises characteristic peaks at the following 2 ⁇ reflection angles: 11.9 ⁇ 0.2°, 14.3 ⁇ 0.2°, 17.5 ⁇ 0.2°, 17.9 ⁇ 0.2°, 18.7 ⁇ 0.2°, 20.4 ⁇ 0.2°, 21.5 ⁇ 0.2°, 22.6 ⁇ 0.2°, 23.0 ⁇ 0.2°, and 24.8 ⁇ 0.2°. More preferably, the XRPD pattern of Beraprost-314d crystal Form III is consistent with Fig. 3 .
  • the present invention provides a Beraprost-314d crystal Form III having an XRPD pattern substantially as shown in Fig.3 .
  • the present invention provides a Beraprost-314d crystal Form III having a DSC thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 61.9 ⁇ 1°C and a peak maximum of approximately 66.2 ⁇ 1°C.
  • the present invention provides a Beraprost-314d crystal Form III having a DSC thermogram pattern substantially as shown in Fig. 4 .
  • the most stable crystalline form at room temperature which has steady physicochemical properties, is preferred and usually selected for use in pharmaceutical formulations and treatment.
  • the Beraprost-314d crystal Form II is a stable crystalline form, which shows good stability with no other crystalline forms during storage under normal storage temperatures (about -20°C) for six months.
  • the Beraprost-314d crystal Form II is a stable crystalline form, which shows good stability with no other crystalline forms during storage at room temperature (about 20 to 25°C) for six months.
  • the Beraprost-314d crystal Form III is not a stable crystalline form at room temperature.
  • the Beraprost-314d crystal Form III will be converted to Beraprost-314d crystal Form II while keeping at room temperature for 1 day at most, as shown in Fig. 5 . This result indicates that the Beraprost-314d crystal Form II is the most stable crystalline form at room temperature.
  • the Beraprost-314d crystal Form II is the most stable crystalline form at room temperature without crystalline form transformation, which can provide steady physicochemical properties for pharmaceutical formulations, and is advantageous in that it can be widely and safely used in storage, shipment, and handling for commercial considerations.
  • X-ray Powder Diffraction (XRPD) Analysis The XRPD patterns were collected on a Bruker D2 PHASER diffractometer with fixed divergence slits and 1D LYNXEYE detector. The samples (ca. 100 mg) were flatly placed on a sample holder. The prepared samples were analyzed over a 2 ⁇ range from 5° to 50° with step size of 0.02 degrees and step time of 1 second using CuK ⁇ radiation at a power of 10 mA and 30 kV. The CuK ⁇ radiation was removed by a divergent beam nickel filter.
  • DSC Differential Scanning Calorimetry
  • the Beraprost-314d crystal Form III (0.5 g, from Example 5) was placed in a glass vial, and isothermal at room temperature for 1 day. Afterwards, the Beraprost-314d crystal Form III was completely converted to Beraprost-314d crystal Form II, as shown in Fig. 5 .

Abstract

The present invention provides crystalline Forms II and III of Beraprost-314d, and processes for the preparation thereof.

Description

    FIELD OF THE INVENTION
  • The present invention relates in general to solid forms of prostacyclin derivatives and in particular, to solid crystalline forms of Beraprost-314d and preparation methods thereof.
    • BACKGROUND OF THE INVENTION
  • Beraprost is a synthetic benzoprostacyclin analogue of natural prostacyclin consisting of four isomers (Beraprost-314d, Beraprost-314d's enantiomer, Beraprost-315d and Beraprost-315d's enantiomer), as shown in Scheme A. Among them, optically pure Beraprost-314d (termed as Esuberaprost, APS-314d or BPS-314d) is the pharmacologically active isomer, and is currently under clinical trials as an added-on active pharmaceutical ingredient in the inhaled treprostinil (Tyvaso®) for the treatment of diseases, such as pulmonary arterial hypertension in North America and Europe. The preparation of Beraprost-314d has been previously described, e.g., in Heterocycles, 2000, 53, 1085-1092, US 8779170 , and WO 2017/174439 .
    Figure imgb0001
  • A stable solid form of Beraprost-314d crystal can be widely used in storage, shipment, and handling for commercial considerations. Additionally, a stable Beraprost-314d crystal having fixed physicochemical properties can provide constant operating parameters, e.g., solubility for regular pharmaceutical formulation and steady bioabsorbability for pharmacological treatment. WO 2017/174439 discloses a crystalline form of Beraprost-314d (termed as Form I). However, it does not disclose the stability data of Beraprost-314d crystal Form I, so it is uncertain whether there exists a crystalline form transformation for Beraprost-314d crystal Form I or not. Thus, the benefits of the conventional crystallization methods for preparing a stable Beraprost-314d crystal cannot be evaluated based on the prior art reference. Consequently, there is a demand for crystallization methods for the preparation of a stable solid form of Beraprost-314d crystal in an efficient and economical way where the novel Beraprost-314d crystal form can remain stable when stored at room temperature for commercial use.
    • SUMMARY OF THE INVENTION
  • According to one aspect, the present invention provides a stable solid form of Beraprost-314d crystal Form II, and processes for the preparation thereof.
  • In one embodiment, the present invention provides a method for preparing a crystalline Form II of Beraprost-314d, which comprises dissolving Beraprost-314d in a first solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, toluene, xylene, acetone, dichloromethane, 1,4-dioxane, tetrahydrofuran, methanol, ethanol, propanol, butanol, and mixtures thereof to form a homogenous solution; lowering the temperature and/or adding a second solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogenous solution; and stirring until a precipitate is formed.
  • In one embodiment, the present invention provides a crystalline Form II of Beraprost-314d having an X-ray powder diffraction (XRPD) pattern exhibiting its five strongest characteristic peaks at the following 2θ reflection angles: 6.1±0.2°, 6.6±0.2°, 7.2±0.2°, 12.1±0.2°, and 16.3±0.2°.
  • In one embodiment, the present invention provides a crystalline Form II of Beraprost-314d having a differential scanning calorimetry (DSC) thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 62.2±1°C and a peak maximum of approximately 67.5±1°C.
  • According to one aspect, the present invention provides a solid form of Beraprost-314d crystal Form III, and processes for the preparation thereof.
  • In one embodiment, the present invention provides a method for preparing a crystalline Form III of Beraprost-314d, which comprises dissolving Beraprost-314d in a third solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, ethyl acetate, isopropyl acetate, dichloromethane, and mixtures thereof to form a homogenous solution; lowering the temperature and/or adding a fourth solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogenous solution; and stirring until a precipitate is formed.
  • In one embodiment, the present invention provides a crystalline Form III of Beraprost-314d having an XRPD pattern exhibiting its five strongest characteristic peaks at the following 2θ reflection angles: 6.2±0.2°, 7.2±0.2°, 12.4±0.2°, 15.7±0.2°, and 19.3±0.2°.
  • In one embodiment, the present invention provides a crystalline Form III of Beraprost-314d having a DSC thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 61.9±1°C and a peak maximum of approximately 66.2±1°C.
  • The present invention provides a solid form of Beraprost-314d crystal Form II, which can remain stable when stored at room temperature without crystalline transformation for commercial use. On the other hand, the prepared Beraprost-314d crystal Form III will slowly convert to Form II while keeping at room temperature It is further proved that the solid form of Beraprost-314d crystal Form II is the most stable form of Beraprost-314d.
    • BRIEF DESCRIPTION OF THE DRAWINGS
    • Fig. 1
    shows an X-ray powder diffraction (XRPD) pattern of Beraprost-314d crystal Form II.
    Fig. 2
    shows a differential scanning calorimetry (DSC) thermogram pattern of Beraprost-314d crystal Form II.
    Fig. 3
    shows an XRPD pattern of Beraprost-314d crystal Form III.
    Fig. 4
    shows a DSC thermogram pattern of Beraprost-314d crystal Form III.
    Fig. 5
    shows the crystalline form transformation from Beraprost-314d crystal Form III to Form II at room temperature for 1 day.
    DETAILED DESCRIPTION OF THE INVENTION Beraprost-314d crystal Form II and Preparation thereof
  • In an embodiment of the present invention, the method for preparing Beraprost-314d crystal Form II comprises the steps of:
    1. (a) dissolving crude Beraprost-314d in a first solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, toluene, xylene, acetone, dichloromethane, 1,4-dioxane, tetrahydrofuran, methanol, ethanol, propanol, butanol, and mixtures thereof to form a homogenous solution;
    2. (b) lowering the temperature and/or adding a second solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogeneous solution;
    3. (c) stirring until a precipitate is formed;
    4. (d) filtering out the precipitate thereby isolating the Beraprost-314d crystal Form II; and
    5. (e) optionally drying the Beraprost-314d crystal Form II.
  • The selection of the first solvent is an important factor to determine whether a Beraprost-314d crystal Form II can be formed. In the present invention, the first solvent used to dissolve the crude Beraprost-314d is selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, toluene, xylene, acetone, dichloromethane, 1,4-dioxane, tetrahydrofuran, methanol, ethanol, propanol, butanol, and mixtures thereof, preferably ethyl acetate and isopropyl acetate. The volume of the first solvent may be about 0.5 ml to about 100 ml, preferably about 1 ml to about 50 ml, and more preferably about 2 ml to about 25 ml, per 1 g of the crude Beraprost-314d. When using isopropyl ether or dichloromethane as the first solvent, the volume is preferably about 20 ml or more. The crude Beraprost-314d can be dissolved in the first solvent at a temperature ranging from about 0°C to about 80°C, preferably from about 10°C to about 70°C, and more preferably from room temperature to about 60°C.
  • In one embodiment of the present invention, the temperature of the homogenous solution is lowered to a temperature ranging from about -30°C to about 60°C, preferably from about -20°C to about 50°C, and more preferably from about -10°C to about 40°C.
  • In a preferred embodiment, the volume of the second solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof may be about 0.5 ml to about 40 ml or about 30 ml or about 20 ml, preferably about 1 ml to about 10 ml, and more preferably about 2 ml to about 5 ml, per 1 ml of the first solvent. The second solvent can be added at a temperature ranging from about -30°C to about 60°C, preferably from about -20°C to about 50°C, and more preferably from about -10°C to about 40°C.
  • In one embodiment of the present invention, the precipitation of the crystal may be performed at a temperature ranging from about -30°C to about 60°C, preferably from about -20°C to about 50°C, and more preferably from about -10°C to about 40°C. In a preferred embodiment, the mixture is stirred in an ice water bath (about 0∼5°C) for a time period, such as for about 18 hours or more, until the precipitate is formed.
  • In one embodiment of the present invention, the step of filtering out the precipitate comprises using the second solvent or a mixture of the first solvent and the second solvent to wash the precipitate. In the mixing solvent, the ratio of the first solvent and the second solvent may be about 1:1 to about 1:100, preferably about 1:2 to about 1:10.
  • In one embodiment of the present invention, the Beraprost-314d crystal Form II has an X-ray powder diffraction (XRPD) pattern exhibiting its five strongest characteristic peaks at the following 2θ reflection angles: 6.1±0.2°, 6.6±0.2°, 7.2±0.2°, 12.1±0.2°, and 16.3±0.2°. In a preferred embodiment, the XRPD pattern further comprises characteristic peaks at the following 2θ reflection angles: 14.3±0.2°, 19.5±0.2°, 19.7±0.2°, 20.6±0.2°, 20.9±0.2°, 21.4±0.2°, 22.3±0.2°, 23.2±0.2°, 24.8±0.2°, and 26.6±0.2°. More preferably, the XRPD pattern of Beraprost-314d crystal Form II is consistent with Fig. 1. The particular data of Beraprost-314d crystal Form II is shown in Table 1. Table 1
    2θ angle (°) d value (Å) relative intensity (%)
    6.1 14.6 100.0
    6.6 13.4 46.1
    7.2 12.4 40.9
    10.4 8.5 12.9
    12.1 7.3 69.0
    13.1 6.7 11.1
    14.3 6.2 27.6
    16.3 5.4 82.4
    16.9 5.2 14.5
    17.5 5.1 7.4
    17.9 5.0 15.8
    18.4 4.8 6.0
    19.1 4.6 13.8
    19.5 4.6 35.0
    19.7 4.5 28.5
    20.2 4.4 11.0
    20.6 4.3 18.2
    20.9 4.3 25.4
    21.4 4.1 21.9
    22.3 4.0 27.8
    22.6 3.9 11.9
    23.2 3.8 32.4
    24.0 3.7 3.5
    24.8 3.6 20.6
    26.3 3.4 10.3
    26.6 3.4 22.0
    27.1 3.3 4.1
    27.6 3.2 9.2
    28.1 3.2 5.2
    28.4 3.1 4.8
    28.7 3.1 4.6
    29.2 3.1 6.5
    29.6 3.0 5.4
    30.5 2.9 4.0
    30.8 2.9 3.4
    31.5 2.8 6.6
    32.7 2.7 4.3
    33.2 2.7 5.8
    33.5 2.7 8.0
    34.4 2.6 3.6
    36.8 2.4 5.7
    37.4 2.4 6.5
    38.2 2.4 3.6
    38.6 2.3 3.8
    40.7 2.2 4.2
    41.0 2.2 4.8
    42.3 2.1 4.9
  • In one embodiment, the present invention provides a Beraprost-314d crystal Form II having an XRPD pattern substantially as shown in Fig.1.
  • In one embodiment, the present invention provides a Beraprost-314d crystal Form II having a differential scanning calorimetry (DSC) thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 62.2±1°C and a peak maximum of approximately 67.5±1°C. In a preferred embodiment, the present invention provides a Beraprost-314d crystal Form II having a DSC thermogram pattern substantially as shown in Fig. 2.
  • Due to the organic solvent system used in the method of the present invention, the precipitated Beraprost-314d crystal Form II possesses compact solid characteristics and thus is easy to be filtered out. Moreover, the residual solvents can be easily removed under high vacuum at room temperature.
  • In addition, Beraprost-314d crystal Form II is a stable crystalline form, which shows good stability, with no other crystalline forms or degraded products of impurities, even after six months of placement under normal storage temperatures (about -20°C).
    • Beraprost-314d crystal Form III and Preparation thereof
  • In an embodiment of the present invention, the method for preparing Beraprost-314d crystal Form III comprises the steps of:
    1. (a) dissolving crude Beraprost-314d in a third solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, ethyl acetate, isopropyl acetate, dichloromethane, and mixtures thereof to form a homogenous solution;
    2. (b) lowering the temperature and/or adding a fourth solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogeneous solution;
    3. (c) stirring until a precipitate is formed;
    4. (d) filtering out the precipitate thereby isolating the Beraprost-314d crystal Form III; and
    5. (e) optionally drying the Beraprost-314d crystal Form III.
  • The selection of the third solvent is an important factor to determine whether a Beraprost-314d crystal Form III can be formed. In the present invention, the third solvent used to dissolve the crude Beraprost-314d is selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, ethyl acetate, isopropyl acetate, dichloromethane, and mixtures thereof, preferably methyl tert-butyl ether and dichloromethane. The volume of the third solvent may be about 0.5 ml to about 100 ml, preferably about 1 ml to about 50 ml, and more preferably about 2 ml to about 25 ml, per 1 g of the crude Beraprost-314d. When using isopropyl ether or dichloromethane as the third solvent, the volume is preferably about 20 ml or more. The crude Beraprost-314d can be dissolved in the third solvent at a temperature ranging from about 0°C to about 80°C, preferably from about 10°C to about 70°C, and more preferably from room temperature to about 60°C.
  • In one embodiment of the present invention, the temperature of the homogenous solution is lowered to a temperature ranging from about 0°C to about 60°C, preferably from about 10°C to about 50°C, and more preferably from about 20°C to about 40°C.
  • In a preferred embodiment, the volume of the fourth solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof may be about 0.5 ml to about 40 ml or about 30 ml or about 20 ml, preferably about 1 ml to about 10 ml, and more preferably about 2 ml to about 5 ml, per 1 ml of the third solvent. The fourth solvent can be added at a temperature ranging from about 0°C to about 60°C, preferably from about 10°C to about 50°C, and more preferably from about 20°C to about 40°C. In a preferred embodiment, the mixture is stirred at room temperature (about 20∼25°C) for a time period, such as for about 18 hours or more, until the precipitate is formed.
  • In one embodiment of the present invention, the precipitation of the crystal may be performed at a temperature ranging from about 0°C to about 60°C, preferably from about 10°C to about 50°C, and more preferably from about 20°C to about 40°C.
  • In one embodiment of the present invention, the step of filtering out the precipitate comprises using the fourth solvent or a mixture of the third solvent and the fourth solvent to wash the precipitate. In the mixing solvent, the ratio of the third solvent and the fourth solvent may be about 1:1 to about 1:100, preferably about 1:2 to about 1:10.
  • In one embodiment of the present invention, the Beraprost-314d crystal Form III has an XRPD pattern exhibiting its five strongest characteristic peaks at the following 2θ reflection angles: 6.2±0.2°, 7.2±0.2°, 12.4±0.2°, 15.7±0.2°, and 19.3±0.2°. In a preferred embodiment, the XRPD pattern further comprises characteristic peaks at the following 2θ reflection angles: 11.9±0.2°, 14.3±0.2°, 17.5±0.2°, 17.9±0.2°, 18.7±0.2°, 20.4±0.2°, 21.5±0.2°, 22.6±0.2°, 23.0±0.2°, and 24.8±0.2°. More preferably, the XRPD pattern of Beraprost-314d crystal Form III is consistent with Fig. 3. The particular data of Beraprost-314d crystal Form III is shown in Table 2. Table 2
    2θ angle (°) d value (Å) relative intensity (%)
    6.2 14.2 100.0
    7.2 12.3 49.4
    9.3 9.5 3.7
    10.2 8.7 11.8
    11.9 7.4 18.5
    12.4 7.1 60.6
    14.3 6.2 18.1
    15.7 5.6 45.9
    17.5 5.1 16.3
    17.9 5.0 14.7
    18.7 4.7 24.9
    19.3 4.6 41.2
    20.4 4.4 19.4
    21.5 4.1 15.1
    22.6 3.9 18.9
    23.0 3.9 19.0
    23.7 3.8 5.6
    24.1 3.7 5.4
    24.8 3.6 14.4
    27.1 3.3 11.2
    27.9 3.2 6.0
    28.8 3.1 3.9
    30.4 2.9 4.5
    31.6 2.8 5.1
    34.1 2.6 4.0
    35.8 2.5 3.9
    36.2 2.5 5.3
    37.8 2.4 5.1
    39.0 2.3 3.3
  • In one embodiment, the present invention provides a Beraprost-314d crystal Form III having an XRPD pattern substantially as shown in Fig.3.
  • In one embodiment, the present invention provides a Beraprost-314d crystal Form III having a DSC thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 61.9±1°C and a peak maximum of approximately 66.2±1°C. In a preferred embodiment, the present invention provides a Beraprost-314d crystal Form III having a DSC thermogram pattern substantially as shown in Fig. 4.
    • Stability of Beraprost-314d crystal Form II
  • For applications in therapeutic fields, the most stable crystalline form at room temperature, which has steady physicochemical properties, is preferred and usually selected for use in pharmaceutical formulations and treatment.
  • In one embodiment, the Beraprost-314d crystal Form II is a stable crystalline form, which shows good stability with no other crystalline forms during storage under normal storage temperatures (about -20°C) for six months.
  • In one embodiment, the Beraprost-314d crystal Form II is a stable crystalline form, which shows good stability with no other crystalline forms during storage at room temperature (about 20 to 25°C) for six months.
  • In one embodiment, the Beraprost-314d crystal Form III is not a stable crystalline form at room temperature. The Beraprost-314d crystal Form III will be converted to Beraprost-314d crystal Form II while keeping at room temperature for 1 day at most, as shown in Fig. 5. This result indicates that the Beraprost-314d crystal Form II is the most stable crystalline form at room temperature.
  • Therefore, the Beraprost-314d crystal Form II is the most stable crystalline form at room temperature without crystalline form transformation, which can provide steady physicochemical properties for pharmaceutical formulations, and is advantageous in that it can be widely and safely used in storage, shipment, and handling for commercial considerations.
    • EXAMPLES
  • X-ray Powder Diffraction (XRPD) Analysis: The XRPD patterns were collected on a Bruker D2 PHASER diffractometer with fixed divergence slits and 1D LYNXEYE detector. The samples (ca. 100 mg) were flatly placed on a sample holder. The prepared samples were analyzed over a 2θ range from 5° to 50° with step size of 0.02 degrees and step time of 1 second using CuKα radiation at a power of 10 mA and 30 kV. The CuKβ radiation was removed by a divergent beam nickel filter.
  • Differential Scanning Calorimetry (DSC) Analysis: The DSC thermogram patterns were collected on a TA DISCOVERY DSC 25 instrument. The samples (ca. 5 mg) were weighed into an aluminum pan with a crimping closed aluminum lid. The prepared samples were analyzed from 10°C to 100°C at a scan rate of 10°C/min under a flow of nitrogen (ca. 50 ml/min). The melting temperature and heat of fusion were calibrated by indium (In) before measurement.
    • Example 1 Preparation of crude Beraprost-314d
  • 2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclope nta[b]benzofuran-5-butanoic acid methyl ester (50.0 g, 121.2 mmol) was dissolved in 200 ml methanol and followed by addition of 200 ml 1N sodium hydroxide/water solution and stirred for 2 hours. The reaction mixture was isolated by acid-base extraction, and the solvent was evaporated off under vacuum. The crude product was purified by chromatography on silica gel using a mixture of hexane and ethyl acetate as a gradient eluent to obtain 33.2 g crude Beraprost-314d.
    • Example 2 Preparation of Beraprost-314d crystal Form II
  • Crude Beraprost-314d (1.00 g, from Example 1) and ethyl acetate (10 ml) were heated to 40°C for dissolution and then cooled to room temperature. N-hexane (20 ml) was added slowly dropwise and the mixture was stirred in ice water bath for 18 hours until solid precipitation occurred. Afterwards, the resulting suspension was filtered and rinsed, and then dried under high vacuum at room temperature for 24 hours to give 0.75 g Beraprost-314d crystal Form II. The XRPD and DSC results are the same as shown in Fig. 1 and Fig. 2.
    • Example 3 Preparation of Beraprost-314d crystal Form II
  • Crude Beraprost-314d (1.00 g, from Example 1) and isopropyl acetate (20 ml) were heated to 40°C for dissolution and then cooled to room temperature. N-heptane (40 ml) was added slowly dropwise and the mixture was stirred in ice water bath for 22 hours until solid precipitation occurred. Afterwards, the resulting suspension was filtered and rinsed, and then dried under high vacuum at room temperature for 24 hours to give 0.73 g Beraprost-314d crystal Form II. The XRPD and DSC results are the same as shown in Fig. 1 and Fig. 2.
    • Example 4 Preparation of Beraprost-314d crystal Form II
  • Crude Beraprost-314d (0.50 g, from Example 1) and acetone (7.5 ml) were heated to 40°C for dissolution and then cooled to room temperature. N-pentane (15 ml) was added slowly dropwise and the mixture was stirred in ice water bath for 20 hours until solid precipitation occurred. Afterwards, the resulting suspension was filtered and rinsed, and then dried under high vacuum at room temperature for 24 hours to give 0.36 g Beraprost-314d crystal Form II. The XRPD and DSC results are the same as shown in Fig. 1 and Fig. 2.
    • Example 5 Preparation of Beraprost-314d crystal Form III
  • Crude Beraprost-314d (1.00 g, from Example 1) and methyl tert-butyl ether (15 ml) were heated to 40°C for dissolution and then cooled to room temperature. N-hexane (30 ml) was added slowly dropwise and the mixture was stirred at room temperature for 18 hours until solid precipitation occurred. Afterwards, the resulting suspension was filtered and rinsed, and then dried under high vacuum at room temperature for 24 hours to give 0.74 g Beraprost-314d crystal Form III. The XRPD and DSC results are the same as shown in Fig. 3 and Fig. 4.
    • Example 6 Preparation of Beraprost-314d crystal Form III
  • Crude Beraprost-314d (0.5 g, from Example 1) and methyl tert-butyl ether (10 ml) were heated to 40°C for dissolution and then cooled to room temperature. N-heptane (20 ml) was added slowly dropwise and the mixture was stirred at room temperature for 20 hours until solid precipitation occurred. Afterwards, the resulting suspension was filtered and rinsed, and then dried under high vacuum at room temperature for 24 hours to give 0.37 g Beraprost-314d crystal Form III. The XRPD and DSC results are the same as shown in Fig. 3 and Fig. 4.
    • Example 7 Preparation of Beraprost-314d crystal Form III
  • Crude Beraprost-314d (0.5 g, from Example 1) and dichloromethane (10 ml) were heated to 40°C for dissolution and then cooled to room temperature. N-pentane (20 ml) was added slowly dropwise and the mixture was stirred at room temperature for 20 hours until solid precipitation occurred. Afterwards, the resulting suspension was filtered and rinsed, and then dried under high vacuum at room temperature for 24 hours to give 0.35 g Beraprost-314d crystal Form III. The XRPD and DSC results are the same as shown in Fig. 3 and Fig. 4.
    • Example 8 Crystalline form transformation from Beraprost-314d crystal Form III to Form II
  • The Beraprost-314d crystal Form III (0.5 g, from Example 5) was placed in a glass vial, and isothermal at room temperature for 1 day. Afterwards, the Beraprost-314d crystal Form III was completely converted to Beraprost-314d crystal Form II, as shown in Fig. 5.

Claims (14)

  1. A crystalline Form II of Beraprost-314d, characterized by having an X-ray powder diffraction (XRPD) pattern comprising its five strongest characteristic peaks at the following 2θ reflection angles: 6.1±0.2°, 6.6±0.2°, 7.2±0.2°, 12.1±0.2°, and 16.3±0.2°.
  2. The crystalline Form II of Beraprost-314d of claim 1, wherein the XRPD pattern further comprises characteristic peaks at the following 2θ reflection angles: 14.3±0.2°, 19.5±0.2°, 19.7±0.2°, 20.6±0.2°, 20.9±0.2°, 21.4±0.2°, 22.3±0.2°, 23.2±0.2°, 24.8±0.2°, and 26.6±0.2°.
  3. The crystalline Form II of Beraprost-314d of claim 1, wherein the XRPD pattern is substantially shown in Fig. 1.
  4. The crystalline Form II of Beraprost-314d of claim 1, further having a differential scanning calorimetry (DSC) thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 62.2±1°C and a peak maximum of approximately 67.5±1°C.
  5. The crystalline Form II of Beraprost-314d of claim 4, wherein the DSC thermogram pattern is substantially shown in Fig. 2.
  6. A method for preparing the crystalline Form II of Beraprost-314d according to claim 1, which comprises the steps of:
    dissolving Beraprost-314d in a first solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, toluene, xylene, acetone, dichloromethane, 1,4-dioxane, tetrahydrofuran, methanol, ethanol, propanol, butanol, and mixtures thereof to form a homogenous solution;
    lowering the temperature and/or adding a second solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogenous solution; and
    stirring in an ice bath until a precipitate is formed,
    provided that when using isopropyl ether or dichloromethane as the first solvent, the volume of the first solvent is about 20 ml or more per 1g of Beraprost-314d.
  7. The method of claim 6, further comprising the steps of:
    adding the second solvent or a mixture of the first solvent and the second solvent for rinsing the precipitate;
    filtering out the precipitate thereby isolating the crystalline Form II of Beraprost-314d; and
    optionally drying the crystalline Form II of Beraprost-314d.
  8. A crystalline Form III of Beraprost-314d, characterized by having an X-ray powder diffraction (XRPD) pattern comprising its five strongest characteristic peaks at the following 2θ reflection angles: 6.2±0.2°, 7.2±0.2°, 12.4±0.2°, 15.7±0.2°, and 19.3±0.2°.
  9. The crystalline Form III of Beraprost-314d of claim 8, wherein the XRPD pattern further comprises characteristic peaks at the following 2θ reflection angles: 11.9±0.2°, 14.3±0.2°, 17.5±0.2°, 17.9±0.2°, 18.7±0.2°, 20.4±0.2°, 21.5±0.2°, 22.6±0.2°, 23.0±0.2°, and 24.8±0.2°.
  10. The crystalline Form III of Beraprost-314d of claim 8, wherein the XRPD pattern is substantially shown in Fig. 3.
  11. The crystalline Form III of Beraprost-314d of claim 8, further comprising a differential scanning calorimetry (DSC) thermogram pattern comprising an endothermic peak with a peak onset temperature of approximately 61.9±1°C and peak maximum of approximately 66.2±1°C.
  12. The crystalline Form III of Beraprost-314d of claim 11, wherein the DSC thermogram pattern is substantially shown in Fig. 4.
  13. A method for preparing the Beraprost-314d crystal Form III according to claim 8, which comprises the steps of:
    dissolving Beraprost-314d in a third solvent selected from the group consisting of ethyl ether, isopropyl ether, methyl tert-butyl ether, ethyl acetate, isopropyl acetate, dichloromethane, and mixtures thereof to form a homogenous solution;
    lowering the temperature and/or adding a fourth solvent selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, and mixtures thereof to the homogenous solution; and
    stirring at room temperature until a precipitate is formed,
    provided that when using isopropyl ether or dichloromethane as the third solvent,
    the volume of the third solvent is about 20 ml or more per 1g of Beraprost-314d.
  14. The method of claim 13, further comprising the steps of:
    adding the fourth solvent or a mixture of the third solvent and the fourth solvent for rinsing the precipitate;
    filtering out the precipitate thereby isolating the crystalline Form III of Beraprost-314d; and
    optionally drying the crystalline Form III of Beraprost-314d.
EP19211631.7A 2018-11-26 2019-11-26 Beraprost-314d crystals and methods for preparation thereof Pending EP3656768A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/199,443 US10577340B1 (en) 2018-11-26 2018-11-26 Beraprost-314d crystals and methods for preparation thereof

Publications (1)

Publication Number Publication Date
EP3656768A1 true EP3656768A1 (en) 2020-05-27

Family

ID=68699212

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19211631.7A Pending EP3656768A1 (en) 2018-11-26 2019-11-26 Beraprost-314d crystals and methods for preparation thereof

Country Status (6)

Country Link
US (1) US10577340B1 (en)
EP (1) EP3656768A1 (en)
JP (1) JP6894490B2 (en)
KR (1) KR102377950B1 (en)
CN (1) CN111217781B (en)
TW (1) TWI727517B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011849A1 (en) * 2001-07-30 2003-02-13 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Process for the production of beraprost and its salts
US8779170B2 (en) 2011-06-16 2014-07-15 Lung Biotechnology Inc. Method of producing beraprost
WO2017174439A1 (en) 2016-04-05 2017-10-12 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of optically active beraprost

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124778A (en) * 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative
JPS59134787A (en) * 1983-01-19 1984-08-02 Toray Ind Inc Preparation of 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative
CN105555276A (en) * 2013-03-15 2016-05-04 格穆斯药业股份有限公司 Beraprost isomer as agent for the treatment of viral infection
JP6440896B2 (en) * 2015-08-12 2018-12-19 ユナイテッド セラピューティクス コーポレイション Method for making beraprost
KR101777632B1 (en) * 2016-04-11 2017-09-12 연성정밀화학(주) Crystalline Forms of Beraprost Sodium and Process of Preparing the Same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011849A1 (en) * 2001-07-30 2003-02-13 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Process for the production of beraprost and its salts
US8779170B2 (en) 2011-06-16 2014-07-15 Lung Biotechnology Inc. Method of producing beraprost
WO2017174439A1 (en) 2016-04-05 2017-10-12 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of optically active beraprost

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BYRN, S. ET AL.: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1995, pages 945 - 954, XP055531015, DOI: 10.1023/A:1016241927429 *
HETEROCYCLES, vol. 53, 2000, pages 1085 - 1092

Also Published As

Publication number Publication date
CN111217781A (en) 2020-06-02
KR20200063072A (en) 2020-06-04
TW202033508A (en) 2020-09-16
JP6894490B2 (en) 2021-06-30
KR102377950B1 (en) 2022-03-24
CN111217781B (en) 2022-05-27
TWI727517B (en) 2021-05-11
US10577340B1 (en) 2020-03-03
JP2020083893A (en) 2020-06-04

Similar Documents

Publication Publication Date Title
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
EP2411394B1 (en) Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
US20080085903A1 (en) Novel crystalline forms of aripiprazole
WO2017008773A1 (en) Crystalline forms of obeticholic acid
EP3656768A1 (en) Beraprost-314d crystals and methods for preparation thereof
JP4657393B2 (en) A novel form of doxazosin mesylate III
EP2977372B1 (en) Polymorphs of febuxostat
EP3656767A1 (en) Beraprost-314d monohydrate crystals and methods for preparation thereof
EP3800175A1 (en) Hexadecyl treprostinil crystals and methods for preparation thereof
EP3907216B1 (en) Crystals of intermediate for benzindene prostaglandins and methods for preparation thereof
EP3594210B1 (en) Lubiprostone crystals and methods for preparing the same
KR102150825B1 (en) Novel sglt-2 inhibitors cocrystal
TW202227387A (en) Treprostinil monohydrate crystals and methods for preparation thereof
WO2023194339A1 (en) Crystalline form of lanifibranor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201126

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210819